Effects of a Renal Rehabilitation Exercise Program in Patients with CKD: Controlled Trial

Misa Miura^{1) 3)}, Aki Hirayama¹⁾, Shigeru Oowada²⁾, Osamu Ito³⁾, Masahiro Kohzuki³⁾

- 1) Department of Health, Tsukuba Univerdity of Technology, Tsukuba, Japan
- ²⁾Asao Clininic, Kawasaki, Japan
- 3) Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine, Sendai, Japan

Objectives:

Hemodialysis patients show reduced physical function and greater risk of arteriosclerosis because of hypertension, metabolic disturbances, and vascular calcification. Meanwhile, exercise training in hemodialysis patients improves fitness, physical function, quality of life, and markers of cardiovascular disease such as arterial stiffness. This study aimed to determine whether aerobic training and electrical stimulation to skeletal muscles for 12 weeks could improve physical function and dialysis efficacy in patients with end-stage renal disease (ESRD).

Methods:

This was a controlled clinical trial. A total of 30 ESRD patients (18 males, 12 females; age: 72.9 ± 7.7 years) (table) were randomized to receive 12 weeks of aerobic training exercise during hemodialysis session (Ex-group: n=14), electrical stimulation to the lower limbs (ES-group: n=6), or no specific intervention (Contgroup: n=10).

The Borg scale was used to control the intensity of training. At baseline and study completion, the primary outcome measures were grip strength, quad muscle torque, workout time, activities, dialysis efficacy, HDL-cholesterol, LDL-cholesterol, Creactive protein (CRP), Interleukin-6 (IL-6) and blood pressure on the morning of the dialysis day.

Weeks

aerobic training (bicycle) exercise(Ex-group: n=14)

electrical stimulation to the lower limbs(ES-group: n=6)

no specific intervention(Cont-group: n=10)

1st Evaluation (at admission)


Final evaluation (after 12W)



aerobic training exercise

(Terasu Erugo, Showa-denki inc, Osaka, Japan)


- During hemodialysis session
- Borg scale: 11~13 RPE
- twice a week
- Work out time: 15~60 min
- Load : 0~43 watt







Position of electrods (lower limb extensors) Portable battery-powered stimulator(REHAB X-2 Cefar, Malmo, Sweden)

- During hemodialysis session
- Intensity : just below pain threshold
- EMS was performed 60 min twice a week
- Pulse width: 0.2msec
- Frequency : 10Hz
- Cyclic stimulation: (20sec ON, 20sec OFF)







Results:

No significant differences between the three groups were noted for the characteristics at the baseline. Data analysis revealed statistically significant improvements of patients in the Ex-group (averaged difference after 12 weeks of exercise as related to initial value: Δ hand grip: +8.6%, Δ quad torque: +8.3%, Δ work out time:+190%, Δactivities: +59.9%, ΔDialysis efficacy: +7.7%, ΔHDL-cholesterol:-9.2%, ΔLDL-cholesterol:-10.4%, ΔCRP: -57.1%, Δblood pressure on the morning of the dialysis day: -8.9%). These effects were not observed in the Contgroup. Meanwhile, in the ES-group (averaged difference after 12 weeks of exercise as related to initial value: Δ quad torque: +33.4%, ΔDialysis efficacy: +6.7%), while the other parameters did not change. Significant difference among three groups were found Quad torque and hand grip.

Conclusions:

In this study, the safety and efficacy of training and electrical stimulation during hemodialysis were confirmed without sudden drop of blood pressure or any other side effects. Therefore, training during hemodialysis session for 12 weeks might improve physical function with specific whole-body effects as well as local effects in ESRD patients.

COI Disclosure: This presentation is not related to any company with a conflict of interest that should be disclosed.

References:

1. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis 2014;64(3):383-93. 3. Howden EJ, Coombes

JS, Strand H, Douglas B, Campbell KL, Isbel NM. Exercise Training in CKD: Efficacy, Adherence, and Safety. Am J Kidney Dis 2015;65(4):583-91.



ePosters supported by F. Hoffmann- I Roche Ltd.



